文献速递白血病

CALCRL是急性髓系白血病的潜在治疗靶点

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2019-06-10

研究在五个国际队列共1500余例AML患者中分析CALCRL表达与生存的关系,发现CALCRL转录水平升高与完全缓解率及生存率降低相关,且在多变量分析中独立于现有风险因素;CALCRL高表达富集白血病干细胞特征,敲除后损害集落形成。

要点

  • CALCRL高表达与AML患者完全缓解率及5年总生存、无事件生存降低相关。
  • CALCRL预后影响在多变量分析及全部验证集中得到确认。
  • CALCRL高表达富集白血病干细胞特征,敲除损害白血病细胞集落形成。

核心结论

  • CALCRL可预测AML结局且超越现有风险因素,是潜在治疗靶点。

研究设计与样本

  • 分析五个国际队列(AMLCG、HOVON、TCGA、Leucegene、UKM)共1500余例特征明确的AML患者的CALCRL表达。

主要发现

  • AMLCG分析队列中,CALCRL低、中、高表达组完全缓解率分别为71.5%、53.7%、49.6%。
  • CALCRL低、中、高表达组5年总生存率分别为43.1%、26.2%、7.1%。
  • CALCRL低、中、高表达组5年无事件生存率分别为29.9%、15.8%、4.7%(均P < 0.001)。
  • CALCRL水平在多变量回归分析中仍与所有终点相关,预后影响在所有验证集中得到确认。
  • CALCRL高表达AML中高表达基因显著富集白血病干细胞特征,CALCRL水平与患者原代样本在免疫缺陷小鼠中的植入能力正相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calcitonin receptor-like (CALCRL) is a G-protein-coupled neuropeptide receptor involved in the regulation of blood pressure, angiogenesis, cell proliferation, and apoptosis, and is currently emerging as a novel target for the treatment of migraine. This study characterizes the role of CALCRL in acute myeloid leukemia (AML). We analyzed CALCRL expression in collectively more than 1500 well-characterized AML patients from five international cohorts (AMLCG, HOVON, TCGA, Leucegene, and UKM) and evaluated associations with survival. In the AMLCG analytic cohort, increasing transcript levels of CALCRL were associated with decreasing complete remission rates (71.5%, 53.7%, 49.6% for low, intermediate, high CALCRL expression), 5-year overall (43.1%, 26.2%, 7.1%), and event-free survival (29.9%, 15.8%, 4.7%) (all P < 0.001). CALCRL levels remained associated with all endpoints on multivariable regression analyses. The prognostic impact was confirmed in all validation sets. Genes highly expressed in CALCRLhigh AML were significantly enriched in leukemic stem cell signatures and CALCRL levels were positively linked to the engraftment capacity of primary patient samples in immunocompromised mice. CRISPR-Cas9-mediated knockout of CALCRL significantly impaired colony formation in human myeloid leukemia cell lines. Overall, our study demonstrates that CALCRL predicts outcome beyond existing risk factors and is a potential therapeutic target in AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Angenendt L, Bormann E, Pabst C, et al. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia. 2019. PMID: 31182782. doi:10.1038/s41375-019-0505-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。